{
    "nct_id": "NCT04835584",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2021-04-08",
    "study_start_date": "2021-05-07",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Dasatinib"
            },
            {
                "drug_name": "Drug: KRT-232"
            },
            {
                "drug_name": "Drug: Nilotinib"
            }
        ]
    },
    "long_title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)",
    "last_updated": "2022-03-21",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Kartos Therapeutics, Inc.",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 109,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Phase 1b and Phase 2 Arms A and B: Documented TP53wt, Ph+, BCR-ABL+ CML-CP",
        "* Phase 2 Arm C ONLY: Documented TP53wt, Ph+, BCR-ABL+ CML-AP",
        "* Subject is resistant (relapsed or refractory) and/or intolerant to at least 1 prior TKI.",
        "* Adults \u2265 18 years of age.",
        "* ECOG performance status of 0 to 2",
        "* Adequate hematologic, hepatic, and renal functions",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Phase 1b and Phase 2 Arms A and B: Documented Ph+, BCR-ABL+ CML-AP",
        "Exclude - * Documented Ph+, BCR-ABL+ CML-BC",
        "Exclude - * Known T315I mutation.",
        "Exclude - * Prior treatment with MDM2 antagonist therapies.",
        "Exclude - * Intolerance to current TKI therapy."
    ],
    "short_title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Kartos Therapeutics, Inc.",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).\n\nThis study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP",
                        "arm_internal_id": 0,
                        "arm_description": "KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: KRT-232",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Dasatinib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Nilotinib",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)",
                        "arm_internal_id": 1,
                        "arm_description": "KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: KRT-232",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Dasatinib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)",
                        "arm_internal_id": 2,
                        "arm_description": "KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: KRT-232",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Nilotinib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)",
                        "arm_internal_id": 3,
                        "arm_description": "KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: KRT-232",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Dasatinib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Nilotinib",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Localized",
                                        "Advanced"
                                    ],
                                    "oncotree_primary_diagnosis": "Myeloid Neoplasm"
                                }
                            },
                            {
                                "and": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "BCR",
                                            "variant_category": "Structural Variation",
                                            "fusion_partner_hugo_symbol": "ABL1"
                                        }
                                    },
                                    {
                                        "genomic": {
                                            "hugo_symbol": "TP53",
                                            "wildtype": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}